Lucid Diagnostics Inc. (LUCD)
NASDAQ:LUCD
Want to see LUCD full AI Analyst Report?
LUCD Stock Chart & Stats
$1.22
>-$0.01(-1.09%)
At close: 4:00 PM EST
$1.22
>-$0.01(-1.09%)
Day’s Range― - ―
52-Week Range$0.90 - $1.63
Previous CloseN/A
Volume130.18K
Average Volume (3M)949.14K
Market Cap
$209.16M
Enterprise Value$104.30M
Total Cash (Recent Filing)$27.88M
Total Debt (Recent Filing)$26.80M
Price to Earnings (P/E)―
Beta0.27
Next Earnings
Aug 17, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding203,066,790
10 Day Avg. Volume1,049,513
30 Day Avg. Volume949,139
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)10.16
Price to Sales (P/S)23.61
P/FCF Ratio-2.39
Enterprise Value/Market Cap0.50
Enterprise Value/Revenue20.32
Enterprise Value/Gross Profit-50.75
Enterprise Value/Ebitda-2.46
Forecast
1Y Price Target
$3.90Price Target Upside219.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.23
Revenue Forecast (FY)$9.94M
Bulls Say, Bears Say
Bulls Say
Commercial Adoption / Test VolumeSustained test volumes above pre-Medicare targets indicate durable physician adoption and clinical workflow fit for EsoCheck/EsoGuard. Higher baseline volume improves prospects for scale economies and revenue growth once reimbursement recognition normalizes, reducing per-test unit costs over time.
Clinical & Guideline MomentumRecognition in guideline drafts and active NIH, registry, and institutional studies materially strengthens clinical credibility. Durable guideline support tends to accelerate payer coverage decisions and physician referral patterns, improving long-term market access and adoption runway.
Improved Liquidity / RunwayFresh capital extending runway into 2027 materially reduces immediate financing pressure and supports continued commercialization investments and payer engagements. A stronger liquidity buffer gives management time to convert demand into collectible revenue as reimbursement milestones progress.
Bears Say
Severe Cash BurnPersistently negative operating and free cash flow signals structural funding risk: continued high quarterly cash outflows mean the company remains dependent on capital markets or debt to fund operations. This constrains strategic flexibility and makes execution contingent on successful financing or rapid reimbursement progress.
High Financial LeverageA debt-heavy capital structure with debt far exceeding equity increases fixed interest obligations and reduces resilience to revenue volatility. High leverage elevates refinancing and covenant risk, making long-term investment and commercialization plans more vulnerable if collections or reimbursement timing slip.
Reimbursement & Collection ConstraintsA large gap between billable amounts and cash-recognized revenue reflects transitional reimbursement status and conservative revenue recognition. Until payor adjudication and Medicare LCD clarity improve, cash realization per test will remain unpredictable, limiting margin sustainability and slowing scalable revenue conversion.
Lucid Diagnostics News
LUCD FAQ
What was Lucid Diagnostics Inc.’s price range in the past 12 months?
Lucid Diagnostics Inc. lowest stock price was $0.90 and its highest was $1.63 in the past 12 months.
What is Lucid Diagnostics Inc.’s market cap?
Lucid Diagnostics Inc.’s market cap is $209.16M.
When is Lucid Diagnostics Inc.’s upcoming earnings report date?
Lucid Diagnostics Inc.’s upcoming earnings report date is Aug 17, 2026 which is in 74 days.
How were Lucid Diagnostics Inc.’s earnings last quarter?
Lucid Diagnostics Inc. released its earnings results on May 14, 2026. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of -$0.063 by -$0.007.
Is Lucid Diagnostics Inc. overvalued?
According to Wall Street analysts Lucid Diagnostics Inc.’s price is currently Undervalued.
Does Lucid Diagnostics Inc. pay dividends?
Lucid Diagnostics Inc. does not currently pay dividends.
What is Lucid Diagnostics Inc.’s EPS estimate?
Lucid Diagnostics Inc.’s EPS estimate is -0.06.
How many shares outstanding does Lucid Diagnostics Inc. have?
Lucid Diagnostics Inc. has 203,066,790 shares outstanding.
What happened to Lucid Diagnostics Inc.’s price movement after its last earnings report?
Lucid Diagnostics Inc. reported an EPS of -$0.07 in its last earnings report, missing expectations of -$0.063. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Lucid Diagnostics Inc.?
Currently, no hedge funds are holding shares in LUCD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lucid Diagnostics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.90 (219.67% Upside)
$3.90 (219.67% Upside)
Hedge Fund Trend
Decreased
By 29.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $245.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 5.9%
Last 30 Days ▼ 5.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.26%
12-Months-Change
Fundamentals
Return on Equity
-370.21%
Trailing 12-Months
Asset Growth
3.92%
Trailing 12-Months
Company Description
Lucid Diagnostics Inc.
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
LUCD Company Deck
LUCD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed a mix of constructive commercial and balance-sheet progress (test volume above targets, LBM policy secured, VA contract and initial PO, strengthened pro forma cash position, favorable draft guideline mention) alongside material near-term reimbursement and collection challenges (Medicare LCD delays, conservative revenue recognition practices, adjudication volatility and denials, elevated burn rate). Management expressed confidence and has positioned to scale once Medicare coverage is issued, but the company currently faces meaningful timing and cash-collection risk that keeps fundamentals mixed.View all LUCD earnings summariesLUCD Stock 12 Month Forecast
Average Price Target
$3.90
▲(219.67% Upside)
Technical Analysis
Ownership Overview
5.36% Insiders
3.47% Mutual Funds
4.40% Other Institutional Investors
82.83% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---